Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 12, 2014
Reporting Period: Fourth quarter and full year ended December 31, 2013.
This filing serves to announce the release of financial results for the period ended December 31, 2013, and to report the issuance of a new patent for the company's product Trokendi XR.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the text of this 8-K.
Material Changes and Events
- Financial Results Announcement: The company issued a press release regarding its fourth quarter and full-year 2013 financial results.
- Intellectual Property: The United States Patent and Trademark Office (USPTO) issued a third patent covering Trokendi XR, a novel once-daily extended-release topiramate product.
Guidance, Outlook, and Risks
Management Commentary: The company scheduled a conference call for March 13, 2014, to review financial results and provide updates on business matters. A live webcast was made available on the company website.
Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties, including those detailed in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 (specifically regarding Convertible Notes).
Legal Disclaimer: Information furnished in this Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2013 financial figures (revenue, net loss, cash position).
- Verify the scope and expiration date of the third patent issued for Trokendi XR via Exhibit 99.2.
- Listen to the archived conference call webcast for management's detailed commentary on the 2013 results and 2014 outlook.
- Consult the Form 10-K (filed March 15, 2013) and Form 10-Q (filed for the quarter ended June 30, 2013) for detailed risk factors and convertible note terms referenced in this filing.